HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $208

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Repligen (NASDAQ: RGEN) and increased the price target from $180 to $208.